Shanghai Henlius Biotech, Inc. Class H (2696) Stock Statistics & Valuation Metrics

Shanghai Henlius Biotech, Inc. Class H has a market cap or net worth of HK$24.78B. The enterprise value is HK$20.78B.

Shanghai Henlius Biotech, Inc. Class H has 163,428,540 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shanghai Henlius Biotech, Inc. Class H’s return on equity (ROE) is 0.27 and return on invested capital (ROIC) is 11.30%.

The current PE Ratio of Shanghai Henlius Biotech, Inc. Class H is 14.74. Shanghai Henlius Biotech, Inc. Class H’s PEG ratio is 1.98.

In the last 12 months, Shanghai Henlius Biotech, Inc. Class H had revenue of 5.72B and earned 820.47M in profits. Earnings per share was 1.51.

In the last 12 months, operating cash flow was 251.26M and capital expenditures -103.69M, giving a free cash flow of 147.58M billion.

Shanghai Henlius Biotech, Inc. Class H pays an annual dividend of ―, resulting in a dividend yield of ―

Shanghai Henlius Biotech, Inc. Class H upcoming earnings date is Aug 14, 2025, TBA Not Confirmed.

Shanghai Henlius Biotech, Inc. Class H as a current ratio of 0.50, with Debt / Equity ratio of 121.06%

In the past 12 months, Shanghai Henlius Biotech, Inc. Class H has paid 25.41M in taxes.

Shanghai Henlius Biotech, Inc. Class H EV to EBITDA ratio is 13.06, with an EV/FCF ratio of 37.00.

Shanghai Henlius Biotech, Inc. Class H has HK$772.96M in cash and marketable securities with ¥3.65B in debt, giving a net cash position of HK$2.88B billion.

Gross margin is 73.10%, with operating margin of 16.41%, and net profit margin of 14.33%.

The average price target for Shanghai Henlius Biotech, Inc. Class H is ―, which is 11.43% higher than the current price. The consensus rating is ―